Alerts will be sent to your verified email
Verify Email
AMBALALSA
|
Ambalal Sarabhai Ent
|
Balaxi Pharma.
|
Gennex Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
0.13 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
24.68 % | 29.33 % | 7.82 % |
|
5yr average Equity Multiplier
|
2.5 | 1.4 | 1.53 |
|
5yr Average Asset Turnover Ratio
|
0.75 | 1.5 | 0.75 |
|
5yr Avg Net Profit Margin
|
12.49 % | 11.83 % | 7.88 % |
|
Price to Book
|
1.94 | 1.19 | 1.51 |
|
P/E
|
55.2 | 11.0 | 17.48 |
|
5yr Avg Cash Conversion Cycle
|
-44.39 Days | 133.11 Days | 43.23 Days |
|
Inventory Days
|
34.61 Days | 68.7 Days | 49.12 Days |
|
Days Receivable
|
54.38 Days | 81.67 Days | 50.53 Days |
|
Days Payable
|
160.49 Days | 60.92 Days | 75.36 Days |
|
5yr Average Interest Coverage Ratio
|
10.58 | 92.41 | 6.21 |
|
5yr Avg ROCE
|
29.87 % | 40.34 % | 11.17 % |
|
5yr Avg Operating Profit Margin
|
4.12 % | 18.05 % | 10.47 % |
|
5 yr average Debt to Equity
|
0.39 | 0.05 | 0.18 |
|
5yr CAGR Net Profit
|
-16.58 % | n/a | 43.63 % |
|
5yr Average Return on Assets
|
9.85 % | 20.09 % | 5.16 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.35 % | 65.99 % | 18.42 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 23.87 % |
|
Change in Promoter Holding (3 Yrs)
|
0.59 % | -6.87 % | -3.63 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Ambalal Sarabhai Ent
|
Balaxi Pharma.
|
Gennex Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|